Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Neoplasms 10Head and Neck Neoplasms 8Carcinoma, Squamous Cell 8Lung Neoplasms 7Leukemia, Myeloid, Acute 7Glioblastoma 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Recurrence 5Pancreatic Neoplasms 5Melanoma 5Leukemia 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Fallopian Tube Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Rectal Neoplasms 3Lymphoma, Follicular 3Colonic Neoplasms 3Brain Neoplasms 3Treatment 2Sarcoma 2Pleural Effusion, Malignant 2Pharyngeal Neoplasms 2

Interventions

Rituximab 4blinatumomab 3Whole-Body Irradiation 3Cyclophosphamide 3fludarabine phosphate 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Clofarabine 2treosulfan 1thymoglobulin 1sabatolimab 1pembrolizumab 1peginterferon alfa-2a 1obinutuzumab 1midostaurin 1ixazomib 1fludarabine 1eribulin 1daratumumab 1acalabrutinib 1Trastuzumab 1Tacrolimus 1Sodium Chloride 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm, Residual × Drug Therapy × Clear all
NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡